Identifiants & Marche
Ticker
ERNA
ISIN
US1140822099
CIK
0000748592
Bourse
NASDAQ
Devise
USD
Entreprise
Pays
US
Siege
N/A
Fondee
N/A
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.